Navigation Links
Amgen to Highlight New Data at Upcoming ESC Congress 2013
Date:8/27/2013

lar Outcomes Following Inhibition of PCSK9 In Different POpulations, is a large and comprehensive clinical trial program evaluating AMG 145.7,8

The Phase 3 clinical trial program for AMG 145 builds upon the successful Phase 2 studies and includes 12 trials, with a combined planned enrollment of more than 27,000 patients.3 The Phase 3 studies will evaluate AMG 145 administered every two weeks and monthly in multiple patient populations, including in combination with statins in patients with hyperlipidemia (LAPLACE-2), in patients with hyperlipidemia who cannot tolerate statins (GAUSS-2), as a stand-alone treatment in patients with hyperlipidemia (MENDEL-2), and in patients whose elevated cholesterol is caused by genetic disorders called heterozygous (RUTHERFORD-2) and homozygous (TESLA and TAUSSIG) familial hypercholesterolemia.7

Five studies of AMG 145 will provide long-term safety and efficacy data, including the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) study, which will assess whether treatment with AMG 145 compared to placebo reduces recurrent cardiovascular events in approximately 22,500 patients with cardiovascular disease.9-13

Additional information about clinical trials of AMG 145 can be found at www.clinicaltrials.gov.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solut
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
2. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
3. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
4. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
5. Amgen Announces Webcast of 2013 Second Quarter Financial Results
6. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
7. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
8. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
9. Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting
10. Amgen And Astellas Announce Japan Alliance
11. Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... July 10, 2014  The U.S. Department of Health ... to University Hospitals (UH) Case Medical Center Seidman Cancer ... model aimed at improving care for patients with complex ... project will test a unique model developed at UH ... disease, significant comorbidities, or demonstrated need for high health ...
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., ... services, has launched the FreeRunner™ knee brace with ... suffer from patella mal-tracking return to active lifestyles. ... than other braces, providing support when patients need ... when they don,t. Patellofemoral issues are ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Nature, not ... intelligence of individual chimpanzees, a new study finds. ... it comes to cognitive [thinking] abilities in chimpanzees," William ... Atlanta, said in a news release from the journal ... give insight into the evolution of intelligence in humans, ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Men who have ... prostate cancer, a new study suggests. But the ... urologists not involved with the study said more research ... truly accurate. For the study, Harvard researchers analyzed ... followed for 24 years, starting in 1986. During that ...
(Date:7/10/2014)... than 200 experts on aggression, who research issues ranging ... the 21st World Meeting of the International Society for ... July 15-19. , Georgia State University is hosting the ... on alternating continents. , "We are excited to be ... countries, which will help produce fresh ideas about the ...
(Date:7/10/2014)... CLEVELAND The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization. ...
(Date:7/10/2014)... studies have shown that more severe illness and even ... secondary respiratory infection after developing influenza. Now, however, a ... determined that if you reverse the order of infection, ... may actually protect against a bad case of the ... protein pneumolysin, which is described as a bacterial virulence ...
Breaking Medicine News(10 mins):Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2
... Caraco Pharmaceutical,Laboratories, Ltd. (NYSE Alternext US: CPD) posted net ... first nine months of Fiscal 2009 of $55.7,million and ... million, respectively, for the third quarter and first nine ... the third quarter of Fiscal 2009,and an increase of ...
... study, presented at The Endocrine Society,s 90th Annual Meeting ... carbohydrates and protein followed by a low-carb, low-calorie diet ... dieters on track with their weight loss program.Lead author, ... Venezuela, along with scientists from Virginia Commonwealth University ...
... division of Ben Venue Laboratories, Inc., announced the ... AP rated and is equivalent to Camptosar(R).,Irinotecan is ... colon or,rectum whose disease has recurred or progressed ... for immediate shipment,nationwide. , ...
... RediClinic LLC today announced that it,has expanded its ... of Texas to include its Austin area clinics. ... an in-network provider for Blue Cross Blue,Shield enrollees. ... in,the Austin area and 15 H-E-B stores in ...
... 117 studies and 25,000 patients to arrive at ranking ... and escitalopram (Lexapro) are the best of 12 new-generation ... analysis shows. , The Italian researchers reviewed 117 studies ... to come to this conclusion. , The drugs tested ...
... First Substantive Legislation that would provide Comprehensive Pancreatic ... ProgressEL SEGUNDO, Calif., Jan. 29 The Pancreatic ... hope in a comprehensive way through research, patient ... applauds U.S. Representatives Anna Eshoo (D-CA) and Ginny ...
Cached Medicine News:Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 7Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 8Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 9Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 10Health News:New Study: Protein in the Morning Helps Dieters Stay on Track and Keep Weight Off 2Health News:Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection 2Health News:RediClinic Locations in Austin Added as Blue Cross and Blue Shield of Texas Network Providers 2Health News:Zoloft, Lexapro the Best of Newer Antidepressants 2Health News:The Pancreatic Cancer Research and Education Act Addresses the Astounding Mortality of the Fourth Leading Cause of Cancer Death in the United States 2Health News:The Pancreatic Cancer Research and Education Act Addresses the Astounding Mortality of the Fourth Leading Cause of Cancer Death in the United States 3